Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy Omission in Hormone Receptor(HR)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor

NCT06996093 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06996093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06996093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy Omission in Hormone Receptor(HR)-Positive/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 2, 2025
Completion date
June 1, 2034
Enrollment
2,508 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer